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BACKGROUND: Type 2 myocardial infarction and myocardial injury are 
common in clinical practice, but long-term consequences are uncertain. 
We aimed to define long-term outcomes and explore risk stratification in 
patients with type 2 myocardial infarction and myocardial injury.
METHODS: We identified consecutive patients (n=2122) with elevated 
cardiac troponin I concentrations (≥0.05 µg/L) at a tertiary cardiac 
center. All diagnoses were adjudicated as per the universal definition 
of myocardial infarction. The primary outcome was all-cause death. 
Secondary outcomes included major adverse cardiovascular events 
(eg, nonfatal myocardial infarction or cardiovascular death) and 
noncardiovascular death. To explore competing risks, cause-specific 
hazard ratios were obtained using Cox regression models.
RESULTS: The adjudicated index diagnosis was type 1 or 2 myocardial 
infarction or myocardial injury in 1171 (55.2%), 429 (20.2%), and 522 
(24.6%) patients, respectively. At 5 years, all-cause death rates were 
higher in those with type 2 myocardial infarction (62.5%) or myocardial 
injury (72.4%) compared with type 1 myocardial infarction (36.7%). 
The majority of excess deaths in those with type 2 myocardial infarction 
or myocardial injury were because of noncardiovascular causes (hazard 
ratio, 2.32; 95% confidence interval, 1.92–2.81 versus type 1 myocardial 
infarction). Despite this finding, the observed crude major adverse 
cardiovascular event rates were similar between groups (30.6% versus 
32.6%), with differences apparent after adjustment for covariates (hazard 
ratio, 0.82; 95% confidence interval, 0.69–0.96). Coronary heart disease 
was an independent predictor of major adverse cardiovascular events in 
those with type 2 myocardial infarction or myocardial injury (hazard ratio, 
1.71; 95% confidence interval, 1.31–2.24).
CONCLUSIONS: Despite an excess in noncardiovascular death, patients 
with type 2 myocardial infarction or myocardial injury have a similar 
crude rate of major adverse cardiovascular events as those with type 1 
myocardial infarction. Identifying underlying coronary heart disease in 
this vulnerable population may help target therapies that could modify 
future risk.
© 2017 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
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The diagnostic criteria for acute myocardial infarc-tion were updated to accommodate the introduc-tion of more sensitive cardiac troponin assays and 
in recognition of the wide range of conditions associ-
ated with myocardial injury.1 The third universal defini-
tion of myocardial infarction recommends a classifica-
tion that is based on etiology, where type 1 myocardial 
infarction is because of plaque rupture or erosion with 
atherothrombotic consequences and type 2 myocardial 
infarction because of myocardial oxygen supply‒de-
mand imbalance in the absence of atherothrombosis. 
Patients with elevated cardiac troponin concentrations 
who do not have overt myocardial ischemia are classi-
fied as having myocardial injury.2 Although these diag-
nostic categories are considered distinct in guidelines, 
implementation in clinical practice has been challeng-
ing because of similarities between patients with type 
2 myocardial infarction and myocardial injury, with the 
implications of these diagnoses uncertain.
The Global Task Force is reviewing the classifica-
tion of myocardial infarction and recognizes the need 
to provide greater clarity for clinicians in practice.3 Al-
though patients with type 2 myocardial infarction and 
myocardial injury have higher crude rates of all-cause 
death compared with those with type 1 myocardial in-
farction,4–9 differences do not always persist in adjusted 
analyses,10,11 and few studies report cause of death or 
risk of future cardiovascular events.12 If patients with 
type 2 myocardial infarction are at increased risk of 
cardiovascular events attributable to atherosclerotic 
disease, then targeted investigation and preventative 
therapies have the potential to modify outcomes.
In consecutive patients with elevated cardiac tropo-
nin concentrations measured using a sensitive assay, we 
previously observed that the diagnosis of type 2 myocar-
dial infarction or myocardial injury was as common as 
type 1 myocardial infarction.4 Here we report outcomes 
for these patients and determine the clinical features as-
sociated with major adverse cardiovascular events, with 
the aim of improving risk stratification in patients with 
type 2 myocardial infarction or myocardial injury.
METHODS
Transparency and Openness Promotion
The analysis code for this study has been made available 
online (Appendix I in the online-only Data Supplement). The 
data will not be made available to other researchers for the 
purposes of reproducing the results because of lack of data 
sharing approval.
Study Population
Consecutive hospital inpatients with elevated cardiac tropo-
nin I concentrations (≥0.05 µg/L) were identified at a tertiary 
cardiac center (Royal Infirmary of Edinburgh, Scotland, United 
Kingdom) during the validation (January 19, 2008‒July 31, 
2008) and implementation (January 19,2009‒July 31, 2009) 
phases of a contemporary sensitive cardiac troponin I assay.4,13 
We included all patients in whom cardiac troponin was 
requested by the attending clinician regardless of suspected eti-
ology or hospital department. All clinical details were obtained 
using an electronic patient record (TrakCare, InterSystems). We 
excluded patients admitted for elective procedures, those with 
incomplete electronic hospital records, and patients who were 
not residents to ensure complete follow-up.
Cardiac Troponin Assay
Plasma cardiac troponin concentrations were measured using a 
contemporary sensitive cardiac troponin I assay (ARCHITECTSTAT, 
Abbott Laboratories, Abbott Park, IL). The study was divided 
into validation and implementation phases.4,13 Only cardiac tro-
ponin concentrations above the diagnostic threshold of the pre-
vious generation assay (≥0.20 µg/L) were reported to clinicians 
during the validation phase, whereas concentrations above a 
revised diagnostic threshold (≥0.05 µg/L) were reported during 
the implementation phase. The 99th percentile of this assay 
is 0.028 µg/L; however, a diagnostic threshold of ≥0.05 µg/L 
was implemented because this was the minimum concentra-
tion where the coefficient of variation was <10% under local 
laboratory conditions. All troponin results were available to the 
research team irrespective of study phase.
Diagnostic Classification
All diagnoses were classified as per the 3rd universal definition 
of myocardial infarction.2,4 Patients were classified as having a 
Clinical Perspective
What Is New?
• We report long-term outcomes at 5 years in con-
secutive patients with type 1 or type 2 myocardial 
infarction or myocardial injury.
• Two-thirds of patients with type 2 myocardial 
infarction or myocardial injury are dead at 5 years, 
with a similar rate of future nonfatal myocardial 
infarction or cardiovascular death as those with 
type 1 myocardial infarction.
• The presence of coronary artery disease is an inde-
pendent predictor of future cardiovascular risk in 
patients with type 2 myocardial infarction or myo-
cardial injury.
What Are the Clinical Implications?
• Clinicians should consider risk stratification in 
patients with type 2 myocardial infarction or myo-
cardial injury for the likelihood of coronary artery 
disease.
• Prospective clinical trials are needed to define the 
efficacy and safety of secondary prevention thera-
pies in patients with type 2 myocardial infarction 
or myocardial injury, which have the potential to 
modify future outcomes.
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type 1 myocardial infarction when myocardial necrosis occurred 
in the context of a presentation with suspected acute coronary 
syndrome with symptoms of myocardial ischemia or evidence 
of myocardial ischemia on the electrocardiogram. Patients with 
symptoms or signs of myocardial ischemia that were thought 
to be because of increased oxygen demand (eg, tachyarrhyth-
mia or hypertrophy) or decreased supply (eg, hypotension, 
hypoxia, or anemia) and myocardial necrosis in the context of 
an alternative clinical diagnosis were classified as having a type 
2 myocardial infarction. Myocardial injury was defined as evi-
dence of myocardial necrosis in the absence of any symptoms 
or signs of myocardial ischemia. For this analysis, we excluded 
patients classified as having type 3, type 4a, type 4b, or type 
5 myocardial infarction. Each case was reviewed and classified 
independently by 2 cardiologists, and any discrepancies were 
resolved by consensus through in-depth review of source data. 
Further information on the adjudication process is provided in 
Appendix II in the online-only Data Supplement.
Clinical Outcomes
Clinical outcomes were identified using local and national 
population registries. We determined death using TrakCare 
(InterSystems) and the National Register of Scotland, with 
future hospitalization for myocardial infarction or heart fail-
ure identified using an extract from the Scottish Morbidity 
Record. We defined death from a cardiovascular cause where 
1 of the following International Classification of Diseases-10 
codes was listed as the primary cause of death: I20‒25, 
I34‒37, I42‒43, I46, I48‒51, and I60‒69 (Appendix III in 
the online-only Data Supplement). The primary outcome was 
all-cause death. Secondary outcomes included major adverse 
cardiovascular events (MACEs; defined as cardiovascular 
death or subsequent myocardial infarction), nonfatal myo-
cardial infarction, fatal myocardial infarction, hospitalization 
with heart failure, and noncardiovascular death. We obtained 
follow-up for all patients until the primary outcome or date of 
censoring (November 16, 2015).
Ethical Considerations
The parent study protocol evaluated the implementation of a 
sensitive cardiac troponin assay and was deemed to fall under 
the remit of audit and service evaluation by the National 
Health Service Lothian Regional Ethics Committee, and there-
fore formal ethical approval was not required. For this study, 
we received approval from the Caldicott guardian to obtain 
long-term follow-up through local and national registries.
Statistical Analysis
Baseline characteristics were summarized as mean (standard 
deviation) or median (interquartile range) as appropriate, with 
patients grouped on the basis of the classification of myo-
cardial infarction. Crude incidence rates for primary and sec-
ondary outcomes were calculated, with risk ratios obtained 
using a generalized linear model with a log link, Poisson error 
distribution, and robust variance estimates.14 We adjusted for 
clinically relevant covariates, including age, sex, renal function 
(estimated glomerular filtration rate), hemoglobin (g/L), dia-
betes mellitus, hypertension, coronary heart disease (defined 
as previous myocardial infarction, coronary revascularization, 
or known angina pectoris), stroke, peripheral vascular dis-
ease, or cigarette smoking. The study period included a low-
ering of the upper reference limit for cardiac troponin from 
0.20 µg/L (validation phase) to 0.05 µg/L (implementation 
phase), and we therefore included a study phase in all mod-
els. We repeated these analyses among only those patients 
who survived 30 days after presentation, defining the start of 
the follow-up period as 30 days after presentation. To explore 
competing risks, cause-specific hazard ratios were obtained 
using Cox regression models for type 1 myocardial infarction 
versus type 2 myocardial infarction or myocardial injury for 
MACE and noncardiovascular death. Penalized splines were 
used to accommodate departures from linearity. We exam-
ined for nonproportional hazards graphically and via the 
method proposed by Grambsch and Therneau.15 In patients 
who survived to 30 days, we explored associations between 
covariates and future risk of MACE. Cumulative incidence 
plots were produced for secondary cardiovascular outcomes, 
which also illustrate the competing risk of noncardiovascu-
lar death. We report 95% confidence intervals (CIs) for all 
estimates, with all analyses performed using R (version 3.2.2) 
using the survival and cmprsk packages.16
RESULTS
We identified 2929 consecutive patients with elevated 
cardiac troponin concentrations (≥0.05 µg/L) of whom 
807 met our exclusion criteria (Figure I in the online-on-
ly Data Supplement). In the study population (n=2122), 
the adjudicated diagnosis was type 1 myocardial infarc-
tion in 1171 patients (55.2%), type 2 myocardial infarc-
tion in 429 patients (20.2%), and myocardial injury in 
522 patients (24.6%; Table 1).
Clinical Characteristics
Patients with type 2 myocardial infarction or myocardial 
injury were older, and there was a higher proportion of 
women than men compared with patients with type 1 
myocardial infarction. Anemia or renal impairment was 
more common in patients with type 2 myocardial infarc-
tion or myocardial injury. A history of previous coronary 
revascularization was more frequent in those with type 1 
myocardial infarction. At presentation, the prescription 
of antiplatelet, antihypertensive, and lipid-lowering ther-
apies was similar across all patients (Table 1). The most 
common diagnoses in patients with type 2 myocardial 
infarction or myocardial injury were cardiac arrhythmia, 
decompensated left ventricular failure, pneumonia, or 
long bone fracture, with variation in prevalence by clas-
sification (Table I in the online-only Data Supplement).
Clinical Outcomes at 5 Years in All 
Patients
During 8809 person-years follow-up (median 4.9 years), 
death from any cause occurred in 1231 patients (58%). In 
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patients with type 2 myocardial infarction, at 5 years, the 
observed risk of death was higher compared with those 
with type 1 myocardial infarction (62.5% versus 36.7%; 
unadjusted relative risk [RR], 2.15; 95% CI, 1.82‒2.55). 
After incorporating age, sex, renal function, hemoglobin, 
and other clinically relevant covariates, the adjusted RR 
fell to 1.51 (95% CI, 1.21–1.87) (Table 2, Figure 1).
The 5-year risk of nonfatal myocardial infarction or 
cardiovascular death (MACE) was similar in patients 
with type 2 compared with type 1 myocardial infarc-
tion (30.1% versus 32.6%; unadjusted RR, 0.92; 95% 
CI, 0.77–1.09) (Figure 2) but lower after adjustment for 
age, sex, and other covariates (adjusted RR, 0.74; 95% 
CI, 0.62–0.88). Adjusting for the same covariates, the 
cause-specific HR for MACEs (with noncardiovascular 
mortality as the competing outcome) was similar to the 
RR (HR, 0.82; 95% CI, 0.69–0.96) (Table 3, Table II in 
the online-only Data Supplement).
Table 1. Baseline Characteristics of the Study Population
Variable
Type 1 Myocardial 
Infarction (n=1171)
Type 2 Myocardial 
Infarction (n=429)
Myocardial Injury 
(n=522) P 
Baseline characteristics
  Age, y, mean (SD) 68 (14) 75 (14) 76 (13) <0.001
  Male, n (%) 709 (60.5) 222 (51.7) 260 (49.8) <0.001
Past medical history, n (%)
  Diabetes mellitus 185 (16.7) 93 (21.7) 96 (18.7) 0.072
  Hypertension 533 (48.2) 254 (59.3) 303 (58.9) <0.001
  Hyperlipidemia 539 (48.6) 177 (41.5) 202 (39.5) 0.001
  Family history 193 (18.1) 14 (3.3) 10 (2.0) <0.001
  Ischemic heart disease 497 (44.7) 191 (44.6) 186 (36.3) 0.004
  Previous myocardial infarction 231 (23.9) 109 (26.0) 107 (20.9) 0.183
  Previous stroke 92 (8.3) 48 (11.2) 86 (16.8) <0.001
  Peripheral vascular disease 85 (7.7) 29 (6.8) 39 (7.6) 0.831
  Previous percutaneous coronary 
intervention
153 (14.7) 17 (4.0) 23 (4.5) <0.001
  Previous coronary artery bypass 
grafting
62 (6.3) 30 (7.1) 32 (6.2) 0.849
  Smoker 380 (34.0) 62 (14.5) 73 (14.0) <0.001
Admission medication, %
  Aspirin 413 (49.7) 175 (44.1) 207 (45.9) 0.141
  Clopidogrel 100 (12.2) 25 (6.3) 26 (5.8) <0.001
  β-Blocker 257 (31.2) 101 (25.7) 111 (24.6) 0.022
  Angiotensin-converting enzyme 
inhibitor
300 (36.4) 136 (34.4) 158 (35.1) 0.782
  Statin 384 (46.5) 156 (39.5) 191 (42.4) 0.054
  Long-acting nitrate 124 (15.1) 48 (12.2) 43 (9.6) 0.017
  Calcium channel blocker 165 (20.1) 65 (16.5) 67 (14.9) 0.050
  Glyceryl trinitrate spray 250 (30.3) 76 (19.3) 63 (14.0) <0.001
  Diuretic 230 (27.9) 170 (43.0) 196 (43.6) <0.001
  Warfarin 35 (4.5) 38 (9.7) 52 (11.6) <0.001
Baseline investigations
  Hemoglobin, g/L, median (IQR) 133.9 (20.4) 121.4 (25) 120.2 (22.1) <0.001
  Urea, mmol/L, median (IQR) 8.2 (9.4) 10 (7.1) 12.02 (11.5) <0.001
  Creatinine, mmol/L, median (IQR) 106.8 (59.8) 132.5 (108.9) 155 (172.2) <0.001
  Corrected eGFR, ml/min, median (IQR) 69 (26) 58 (28) 54 (32) <0.001
  Cholesterol, mmol/L, median (IQR) 4.8 (1.3) 4.3 (1.2) 4.3 (1.4) <0.001
  Troponin I, µg/L 2.42 (0.27–15.23) 0.14 (0.07–0.66) 0.13 (0.06–0.39) <0.001
Values are mean (SD), median (IQR), or n (%). P values obtained from groupwise comparisons using χ2, Kruskal Wallis, or 1-way analysis 
of variance tests, as appropriate.
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For the individual components of MACEs, the risk of 
nonfatal myocardial infarction was lower in those with type 
2 myocardial infarction compared with type 1 myocardial 
infarction (10.0% versus 17.8%; adjusted RR, 0.58; 95% 
CI, 0.44–0.77). Although the crude rates of cardiovascular 
death were higher for type 2 myocardial infarction com-
pared with type 1 myocardial infarction (24.2% versus 
21.6%), the adjusted relative risk was lower at 0.85 (95% 
CI, 0.70–1.03). Risks of fatal myocardial infarction and 
hospitalization with heart failure were comparable across 
groups (Table 2). Noncardiovascular death was higher in 
patients with type 2 myocardial infarction compared with 
type 1 myocardial infarction (35.7% versus 13.2%; ad-
justed RR, 1.66; 95% CI, 1.40–1.98) (Figure 2).
We found similar relative risks for patients with myocar-
dial injury compared with type 1 myocardial infarction for 
most primary and secondary outcomes, but a lower risk of 
nonfatal myocardial infarction and higher risk of noncar-
diovascular death were observed. Patients with myocar-
dial injury had a higher risk of all-cause death and heart 
failure hospitalization than patients with type 2 myocardi-
al infarction (Table III in the online-only Data Supplement).
Clinical Outcomes at 5 Years in Those 
Who Survive to 30 Days
In patients who survived from their initial presenta-
tion to 30 days, death from any cause occurred in 31% 
Table 2. Death and Major Cardiovascular Events at 5 Years, by Diagnosis
Variable
Type 1 MI 
(n=1171)
Type 2 MI 
(n=429)
Myocardial 
Injury (n=522)
Type 2 MI Versus Type 1 MI Myocardial Injury Versus Type 1 MI
Unadjusted RR 
(95% CI)
Adjusted RR 
(95% CI)
Unadjusted RR 
(95% CI)
Adjusted RR 
(95% CI)
Death from any cause 430 (36.7) 268 (62.5) 378 (72.4) 2.15 (1.82–2.55) 1.51 (1.21–1.87) 2.88 (2.43–3.40) 2.09 (1.72–2.55)
Major adverse 
cardiovascular event
382 (32.6) 129 (30.1) 162 (31.0) 0.92 (0.77–1.09) 0.74 (0.62–0.88) 0.95 (0.81–1.11) 0.77 (0.66–0.89)
  Nonfatal MI 209 (17.8) 43 (10.0) 35 (6.7) 0.60 (0.45–0.79) 0.58 (0.44–0.77) 0.43 (0.31–0.58) 0.44 (0.32–0.60)
  Cardiovascular death 253 (21.6) 104 (24.2) 145 (27.8) 1.11 (0.92–1.34) 0.85 (0.70–1.03) 1.25 (1.07–1.46) 0.92 (0.79–1.07)
Fatal MI 32 (2.7) 9 (2.1) 18 (3.4) 0.81 (0.45–1.46) 0.64 (0.37–1.11) 1.17 (0.81–1.71) 0.93 (0.64–1.34)
Heart failure hospitalization 103 (8.8) 25 (5.8) 48 (9.2) 0.71 (0.50–1.02) 0.77 (0.54–1.12) 1.03 (0.81–1.32) 1.08 (0.86–1.35)
Noncardiovascular death 155 (13.2) 153 (35.7) 218 (41.8) 2.33 (1.99–2.71) 1.66 (1.40–1.98) 2.54 (2.33–2.89) 1.84 (1.61–2.11)
CI indicates confidence interval; MI, myocardial infarction; and RR, relative risk. Event rates are n (%) for primary and secondary outcomes with adjusted RR and 
95% CI at 5 years. For the composite of major adverse cardiovascular events, patients who experienced nonfatal myocardial infarction and subsequent cardiovascular 
death are counted once. Cause of death was not determined in 48 patients because of missing data.
Figure 1. Kaplan‒Meier curves illustrating risk of death from any cause at 5 years stratified by index diagnosis, 
with table of number at risk.  
Pairwise comparison of groups obtained using the log-rank test. MI indicates myocardial infarction.
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(333/1074) of patients with type 1 myocardial infarction, 
56.1% (207/368) of patients with type 2 myocardial in-
farction, and 67% (293/437) of patients with myocardial 
injury (Table IV in the online-only Data Supplement). The 
adjusted RR of death for patients with type 2 versus type 
1 myocardial infarction was similar to that observed in the 
total population (adjusted RR, 1.52; 95% CI, 1.21–1.92). 
For all but 1 of the secondary outcomes, the relative risks 
were similar to those obtained in the main analysis. How-
ever, the association between type of myocardial infarc-
tion and risk of MACE was weaker than was observed 
in the whole population, occurring in 27.4% (101/368) 
of patients with type 2 myocardial infarction and 27.7% 
(298/1074) of patients with type 1 myocardial infarction, 
with an adjusted RR of 0.80 (95% CI, 0.65–0.98).
In patients with type 2 myocardial infarction or myo-
cardial injury, age, declining renal function, a history of di-
abetes mellitus, peripheral vascular disease, and coronary 
artery disease were independent predictors of MACEs at 
5 years (Table V in the online-only Data Supplement). The 
presence of coronary artery disease was associated with 
an increase in the cause-specific hazard ratio for MACEs 
at 5 years (HR, 1.71; 95% CI, 1.31–2.24) compared with 
those without coronary artery disease. When compared 
with patients with type 1 myocardial infarction, patients 
with type 2 myocardial infarction or myocardial injury 
with coronary artery disease had a higher risk of a MACE 
(RR, 1.56; 95% CI, 1.29–1.88). The adjusted cause-spe-
cific hazard ratio for MACE, which accounts for compet-
ing risk from noncardiovascular death, was 1.05 (95% 
CI, 0.85–1.30) (Figure  3). On discharge from hospital, 
patients with type 2 myocardial infarction or myocardial 
injury and a history of coronary artery disease were less 
likely than those with type 1 myocardial infarction to be 
prescribed aspirin (66.2% versus 90.7%), a statin (69.2% 
versus 86.0%), or an angiotensin converting enzyme in-
hibitor (52.9% versus 71.3%, P<0.001 for all) (Table 4).
DISCUSSION
In a cohort of consecutive hospitalized patients with 
elevated cardiac troponin concentrations, we classified 
Figure 2. Cumulative incidence curves illustrating risk of major adverse cardiovascular events (type 1 myocardial in-
farction [MI] or cardiovascular death) and competing risk of noncardiovascular death at 5 years stratified by index 
diagnosis.
Table 3. Cause-Specific Hazard Ratio for Major 
Adverse Cardiovascular Event and Noncardiovascular 
Death in Patients With Type 2 Myocardial Infarction or 
Myocardial Injury Versus Type 1 Myocardial Infarction 
in Unadjusted and Fully Adjusted Cox-Regression 
Models
Variable
Cause-Specific Hazard Ratio 
(95% CI) P Value
Major adverse cardiovascular event
  Model 1* 1.16 (1.00–1.34) 0.052
  Model 2† 0.84 (0.72–0.98) 0.024
  Model 3‡ 0.74 (0.63–0.87) <0.001
  Model 4§ 0.82 (0.69–0.96) 0.016
Noncardiovascular death
  Model 1* 3.73 (3.15–4.41) <0.001
  Model 2† 2.63 (2.21–3.12) <0.001
  Model 3‡ 2.27 (1.90–2.72) <0.001
  Model 4§ 2.32 (1.92–2.81) <0.001
Type 1 myocardial infarction is the referent group. P value for inclusion of 
index diagnosis term.
*Unadjusted.
†Adjusted for age and sex.
‡As per model 2, with adjustment for estimated glomerular filtration rate.
§As per model 3, with adjustment for hemoglobin, smoking, diabetes 
mellitus, hypertension, coronary artery disease, stroke, peripheral vascular 
disease, and study phase.
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the diagnosis of myocardial infarction according to the 
universal definition and report outcomes after 5 years 
follow-up. We make several observations that have im-
plications for clinical practice. First, greater than two 
thirds of patients with type 2 myocardial infarction or 
myocardial injury do not survive to 5 years after index 
diagnosis. This mortality rate was twice that of patients 
with type 1 myocardial infarction, with differences pri-
marily because of an excess in noncardiovascular deaths. 
Second, MACEs occurred in one third of patients, and 
rates were similar irrespective of diagnostic classifica-
tion. In those patients with type 2 myocardial infarction 
or myocardial injury, the presence of coronary heart dis-
ease was 1 of the strongest predictors of a MACE. Those 
patients with type 2 myocardial infarction or myocardial 
injury with known coronary artery disease were less like-
ly to receive secondary prevention therapies compared 
with those with type 1 myocardial infarction. Identifying 
patients with elevated cardiac troponin concentrations 
in the context of an acute illness who have underlying 
coronary heart disease may provide an opportunity for 
clinicians to improve the targeting of preventative thera-
pies and reduce the risk of cardiovascular events.
Several studies demonstrate that the diagnosis of 
type 2 myocardial infarction is common in clinical prac-
tice. It is responsible for between 2% and 37% of all 
elevations in cardiac troponin in unselected hospitalized 
patients and between 5% to 71% in unselected pa-
tients attending the emergency department.17–21 Myo-
cardial injury has been reported in ≤70% of unselected 
patients,5,22 but because the frequency of diagnosis is 
not reported by the majority of studies, failure to clas-
sify patients according to the criteria set out in the 
universal definition may inflate the incidence of type 2 
myocardial infarction.23 Both type 2 myocardial infarc-
tion and myocardial injury increase the risk of all-cause 
death at ≤3 years.5–9,21,23–25 We now provide outcome 
data at 5 years demonstrating that two thirds of pa-
tients with type 2 myocardial infarction or myocardial 
injury are dead with twice the event rate of patients 
with type 1 myocardial infarction.
One of the key limitations of prior analyses is that the 
majority have not reported the specific cause of death, 
and therefore estimates of the proportion of events 
that may be attributable to cardiovascular disease are 
lacking.26,27 We found that the excess in all-cause death 
in patients with type 2 myocardial infarction or myocar-
dial injury was largely attributable to a 3-fold increase in 
noncardiovascular death. Because patients with type 2 
myocardial infarction or myocardial injury are older and 
have a higher prevalence of anemia, renal impairment, 
and other comorbidities, this outcome is perhaps un-
surprising. Nonetheless, it is notable that the crude risk 
of MACEs in patients with type 2 myocardial infarction 
or myocardial injury was similar to that in patients with 
type 1 myocardial infarction. In models taking into ac-
count the differences in age, sex, and other character-
istics between patients with different index diagnoses, 
the risk of subsequent cardiovascular events was ≈25% 
lower in patients with type 2 myocardial infarction or 
myocardial injury than in patients with type 1 myo-
cardial infarction. This may in part be attributable to 
competing risks, with the much higher rates of noncar-
diovascular death reducing the pool of patients at risk 
Figure 3. Cumulative incidence curves illustrating risk of major adverse cardiovascular events (type 1 myocardial 
infarction or cardiovascular death) and competing risk of noncardiovascular death in those who survive to 30 days 
in patients with type 1 myocardial infarction and in those with type 2 myocardial infarction or myocardial injury 
stratified by known CAD.  
CAD indicates coronary artery disease; and MI, myocardial infarction.
 by guest on July 9, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
Chapman et al Long-Term Outcomes of Type 2 Myocardial Infarction
Circulation. 2018;137:1236–1245. DOI: 10.1161/CIRCULATIONAHA.117.031806 March 20, 2018 1243
ORIGINAL RESEARCH 
ARTICLE
of having a cardiovascular event. However, competing 
risks are not the only explanation for the lower rates of 
MACE in patients with type 2 myocardial infarction or 
myocardial injury, as in an adjusted analysis taking into 
account competing risks and other clinical variables, a 
difference in the cause-specific hazard ratio was still ap-
parent between the groups.
The diagnostic distinction between patients with 
type 2 myocardial infarction and myocardial injury is 
challenging but worthwhile if the diagnosis conveys im-
portant prognostic information or influences treatment 
decisions.7,28–30 In our analysis, the recommended clas-
sification of type 2 myocardial infarction or myocardial 
injury did not differentially identify those patients at risk 
of a MACE. This observation is consistent with previous 
studies and suggests that alternate strategies for risk 
stratification may be required. In patients with type 2 
myocardial infarction, the presence of obstructive coro-
nary artery disease may influence prognosis. Outcomes 
from the SWEDEHEART registry (Swedish Web-system 
for Enhancement and Development of Evidence-based 
care in Heart disease Evaluated According to Recom-
mended Therapies) of 41 817 patients with type 1 or 2 
myocardial infarction demonstrated an increased risk of 
all-cause death in patients with type 2 myocardial infarc-
tion with obstructive coronary artery disease compared 
with those without.21 Similarly, in a recent analysis of 
the APACE cohort (Advantageous Predictors of Acute 
Coronary Syndromes Evaluation), Nestelberger et al31 
found that patients with type 2 myocardial infarction 
and coronary artery disease had a 90-day cardiovascu-
lar mortality of 3.6%, with no deaths observed in those 
without coronary artery disease. Our analysis supports 
these findings, with coronary artery disease 1 of the 
strongest predictors of MACEs in patients with type 2 
myocardial infarction or myocardial injury. The preva-
lence of coronary artery disease in patients with type 2 
myocardial infarction or myocardial injury was 42% in 
our cohort and varies between 36% and 78% in previ-
ous reports.7,11,21,22,32 However, estimates obtained from 
registry studies are hindered by selection bias because 
those who undergo angiography will have a higher pre-
test probability of coronary artery disease, therefore the 
true prevalence of coronary artery disease in this group 
of patients remains uncertain.33
It is important to note that patients with type 2 
myocardial infarction or myocardial injury receive fewer 
prescriptions for preventative therapies compared with 
those with type 1 myocardial infarction.9,10,20–23 To date, 
no randomized controlled trials have evaluated sec-
ondary prevention in this population, and there are no 
formal recommendations for risk assessment or treat-
ment.30 Given the current heterogeneity in application 
of the universal definition of myocardial infarction, 
the feasibility of delivering such a study with compa-
rable observations across multiple healthcare settings 
is uncertain. Primary prevention guidelines recommend 
statin therapy where the predicted 10-year risk of ad-
verse cardiovascular events is >10%.34 In our study, for 
patients who survive their initial presentation with type 
2 myocardial infarction and are not already known to 
have coronary artery disease, the rate of MACEs  is 
>10% at 1 year. Although this outcome may be par-
tially attributable to age and the presence of comorbid-
ities, a significant proportion may have unrecognized 
coronary artery disease and may benefit from further 
investigation or preventative therapies.
We believe that clinicians should adopt a pragmat-
ic approach and risk stratify individual patients on the 
basis of their likelihood of coronary artery disease.29,30 
There are no risk assessment tools validated for use in 
this setting, therefore clinicians must review the pre-
senting symptoms, medical history, cardiovascular risk 
factors, serial 12-lead electrocardiograms, and any 
available imaging findings and apply clinical judgment. 
Where the probability of coronary disease is high, it may 
be reasonable to commence secondary prevention with 
aspirin and a statin in the absence of contraindications. 
If patients with type 2 myocardial infarction are found 
Table 4. Recommended Therapies at Discharge in 
Patients With Type 1 Myocardial Infarction, Type 2 
Myocardial Infarction, and Myocardial Injury Who 
Survive to 30 Days, Stratified by the Presence of 
Coronary Artery Disease
Variable
Type 1 
Myocardial 
Infarction 
(n=1074)
Type 2 
Myocardial 
Infarction or 
Myocardial 
Injury/Known 
Coronary 
Artery Disease 
(n=325)
Type 2 
Myocardial 
Infarction or 
Myocardial 
Injury/No 
Known 
Coronary Artery 
Disease (n=467)
P 
Value
Aspirin 896 (90.7) 190 (66.2)* 148 (37.7%) <0.001
Clopidogrel 823 (80.7) 52 (17.6)* 31 (7.6%) <0.001
β-Blocker 651 (64.2) 126 (42.6)* 97 (23.7%) <0.001
Angiotensin-
converting 
enzyme 
inhibitor
724 (71.3) 156 (52.9)* 124 (30.2%) <0.001
Statin 872 (86.0) 204 (69.2)* 120 (29.3%) <0.001
Long-acting 
nitrates
143 (14.1) 77 (26.1)* 12 (2.9%) <0.001
Glyceryl 
trinitrate 
spray
671 (66.0) 121 (41.0)* 23 (5.6%) <0.001
Calcium 
channel 
blockers
165 (16.3) 67 (22.7) 43 (10.5%) <0.001
Warfarin 33 (3.4) 44 (15.0)* 64 (15.6%) <0.001
Values are n (%). P values obtained from groupwise comparison using χ2 
test.
*P<0.001 in post hoc analysis comparing patients with type 2 myocardial 
infarction or myocardial injury with coronary artery disease versus patients with 
type 1 myocardial infarction.
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to have obstructive coronary artery disease, revascular-
ization could plausibly reduce the risk of future cardiac 
events, but this strategy has not been evaluated. Where 
the probability of coronary disease is intermediate or 
low, further investigation (invasive or CT coronary angi-
ography) should be considered to identify patients with 
underlying coronary artery disease, where the benefits of 
secondary prevention are well recognized. The optimal 
timing for investigation in this group of patients is also 
uncertain. Where the probability of type 1 myocardial 
infarction is high, invasive assessment should be consid-
ered on an urgent basis in line with standard practice. 
In those patients where myocardial injury or infarction 
is secondary to oxygen supply‒demand imbalance, fur-
ther assessment may need to be deferred until patients 
have recovered from their primary illness. Furthermore, 
a recognition that these patients are at increased risk of 
noncardiovascular events may lead to an improvement 
in outcomes, through better monitoring or intensifica-
tion of treatment of the primary presenting condition.
There are important limitations to the data presented. 
The study population was identified on the basis of an 
elevated troponin I concentration measured using a con-
temporary sensitive assay with a diagnostic threshold of 
0.05 µg/L, and the true prevalence of myocardial injury 
and infarction could be higher using a lower threshold 
or a high-sensitivity cardiac troponin assay. Although 2 
cardiologists adjudicated index diagnoses using all avail-
able clinical information, with excellent intraobserver 
agreement, there remains potential for misclassification, 
particularly for type 2 myocardial infarction and myocar-
dial injury. There is likely to be variation in the in-hospital 
treatments received, which we could not adjust for, 
and we could not adjust for illness severity. As previ-
ously reported, a low proportion of patients with type 
2 myocardial infarction or myocardial injury underwent 
inpatient coronary angiography.4 We therefore defined 
coronary artery disease on the basis of a diagnosis of 
angina, previous myocardial infarction, or previous coro-
nary revascularization, which is likely to significantly un-
derestimate the prevalence of coronary artery disease. 
Last, subsequent hospitalizations and cardiovascular or 
noncardiovascular death were determined using Inter-
national Classification of Diseases-10 coding obtained 
from regional and national registry data, where there is 
the potential for both diagnostic and coding errors. We 
were therefore not able to determine the incidence of 
subsequent type 1 or type 2 myocardial infarction.
CONCLUSIONS
More than two thirds of patients admitted to hospital 
with type 2 myocardial infarction or myocardial injury 
die in ≤5 years, with the majority of deaths because of 
noncardiovascular causes. Nonetheless, MACEs occur 
in one third of patients with elevated cardiac troponin 
concentrations, irrespective of whether myocardial ne-
crosis was spontaneous or secondary to another acute 
illness. Although patients with type 1 myocardial infarc-
tion were at highest risk, there was no separation of 
risk between those with a diagnosis of type 2 myocar-
dial infarction or myocardial injury. In contrast, those 
patients with type 2 myocardial infarction or myocar-
dial injury known to have coronary artery disease are 
at highest risk of cardiovascular events, and efforts to 
diagnose coronary artery disease may provide oppor-
tunities to target preventative therapies and improve 
patient outcomes.
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Supplemental Table 1. Most common primary discharge diagnoses in patients with an 
adjudicated diagnosis of type 2 myocardial infarction or myocardial injury.  
 
 
  
Type 2 Myocardial Infarction Myocardial Injury 
Arrhythmia (19.1%, 82/429) Heart Failure (12.8%, 67/522) 
Pneumonia (13.5%, 58/429) Arrhythmia (10.9%, 57/522) 
Heart Failure (12.4%, 53/429) Pneumonia (9.6%, 50/522) 
Fracture (4.2%, 18/429) Fracture (8.0%, 42/522) 
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Supplemental Table 2 – Cause-specific hazard ratios for major adverse cardiovascular 
events in all patients.  
 
 
Penalised smoothing splines used for age and eGFR (estimated glomerular filtration rate) in multivariate model. Type 1 Myocardial Infarction as 
referent group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Major Adverse Cardiovascular Events (MACE)  
 Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) 
Age (per 10-year increase) 1.60 (1.50-1.70) - 
Sex (male) 0.85 (0.73-0.98) 1.09 (0.93-1.28) 
Haemoglobin (per 10 g/L reduction) 1.18 (1.14-1.21) 1.07 (1.03-1.11) 
eGFR (per 10 ml/min reduction) 1.20 (1.17-1.24) - 
Smoking 0.66 (0.55-0.79) 1.26 (1.02-1.56) 
Diabetes Mellitus 1.77 (1.49-2.10) 1.36 (1.14-1.64) 
Hypertension 1.66 (1.42-1.93) 1.05 (0.89-1.24) 
Coronary Artery Disease 2.52 (2.16-2.94) 1.80 (1.52-2.14) 
Stroke 1.88 (1.53-2.31) 1.10 (0.89-1.38) 
Peripheral Vascular Disease 2.07 (1.65-2.59) 1.45 (1.14-1.86) 
Validation phase 1.21 (1.04-1.40) 1.16 (0.99-1.35) 
Type 1 Myocardial Infarction 1.00 1.00 
Type 2 Myocardial Infarction / 
Myocardial Injury 1.16 (1.00-1.34) 0.82 (0.69-0.96) 
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Supplemental Table 3 – Adjusted relative risks of primary and secondary outcomes for 
patients with myocardial injury versus type 2 myocardial infarction  
 
 
 Myocardial Injury versus  
Type 2 MI 
 
Adjusted RR  
(95% CI) 
Death from any cause 1.27 (1.08-1.48) 
MACE  0.99 (0.87-1.13) 
   Non-fatal MI  0.80 (0.61-1.03) 
   Cardiovascular death 1.07 (0.94-1.22) 
Fatal MI 1.18 (0.87-1.58) 
Heart failure hospitalization 1.23 (1.03-1.46) 
Non-cardiovascular death 1.12 (0.99-1.26) 
 
Models adjusted for age, gender, renal function, haemoglobin and history of hypertension, stroke, peripheral vascular disease,  
diabetes mellitus, smoking, coronary artery disease and study phase.  
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Supplemental Table 4. Death and major cardiovascular events at 5 years stratified by diagnosis in those who survived index hospitalization  
 
 
 Type 1 MI  
(n=1,074) 
Type 2 MI 
(n=368) 
Myocardial injury 
(n=437) 
Type 2 MI versus  
Type 1 MI 
 
Adjusted RR  
(95% CI) 
Myocardial Injury 
versus Type 1 MI 
 
Adjusted RR  
(95% CI) 
Death from any cause 333 (31.0%) 207 (56.1%) 293 (67.0%) 1.52 (1.21-1.92) 1.95 (1.60-2.39) 
MACE  298 (27.7%) 101 (27.4%) 135 (30.9%) 0.80 (0.65-0.98) 0.87 (0.73-1.02) 
   Non-fatal MI  198 (18.4%) 41 (11.1%) 34 (7.8%) 0.60 (0.45-0.81) 0.46 (0.34-0.64) 
   Cardiovascular death 172 (16.0%) 77 (20.9%) 118 (27.0%) 0.95 (0.76-1.18) 1.07 (0.90-1.27) 
Fatal MI 32 (3.0%) 9 (2.4%) 17 (3.9%) 0.65 (0.38-1.14) 0.90 (0.61-1.31) 
Heart failure hospitalization 92 (8.6%) 22 (6.0%) 39 (8.9%) 0.86 (0.58-1.26) 1.18 (0.91-1.52) 
Non-cardiovascular death 145 (13.5%) 121 (32.8%) 162 (37.1%) 1.55 (1.28-1.88) 1.61 (1.38-1.88) 
	Supplemental Table 5. – Cause-specific hazard ratios for major adverse cardiovascular 
events in patients with type 2 myocardial infarction or myocardial injury alone who survive 
from their initial presentation to 30 days; unadjusted and fully adjusted cox-regression 
models. 
 
 
 Major Adverse Cardiovascular Events (MACE)  
 Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) 
Age (per 10-year increase) 1.56 (1.39-1.75) 1.53 (1.34-1.75) 
Sex (male) 1.08 (0.84-1.38) 1.26 (0.97-1.64) 
Haemoglobin (per 10 g/L reduction) 1.10 (1.04-1.16) 1.04 (0.99-1.10) 
eGFR (per 10 ml/min reduction) 1.16 (1.10-1.21) 1.11 (1.05-1.17) 
Smoking 0.86 (0.60-1.23) 1.39 (0.94-2.05) 
Diabetes Mellitus 1.79 (1.36-2.35) 1.50 (1.12-2.01) 
Hypertension 1.61 (1.24-2.10) 1.02 (0.76-1.36) 
Stroke 1.54 (1.12-2.13) 1.12 (0.80-1.55) 
Peripheral Vascular Disease 2.43 (1.68-3.50) 1.82 (1.21-2.74) 
Validation phase 1.19 (0.92-1.53) 1.25 (0.96-1.63) 
Coronary Artery Disease  2.21 (1.73-2.83) 1.71 (1.31-2.24) 
  eGFR = estimated glomerular filtration rate. Patients without coronary artery disease as referent group.   
 
 
 
	
 
 
	 
 
Supplemental Figure 1. – CONSORT Diagram with identification of the study population. 
Consecutive patients with elevation in cardiac troponin concentration were identified (≥0.05 
µg/L). We excluded patients who underwent elective procedures, residents not local to our 
region or with missing or incomplete records. After adjudication, we excluded those with Type 
3-5 myocardial infarction.  
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	Supplemental Appendix 1. Analysis code 
 
All analysis was performed using R (version 3.2.2) using the survival and cmprsk packages. 
For transparency, the analysis code is available open source via GitHub.3  
 
Available at https://github.com/a-r-chapman/type_2_outcomes 
	
  
Upper reference limit = 0.05 µg/L 
 
 
	
Supplemental Appendix 2. Additional information on diagnostic adjudication  
 
Criteria for adjudication of patients with myocardial necrosis 
 
 
Type 1 myocardial infarction 
 
Myocardial necrosis (any cardiac troponin I [cTnI] 
concentration above the upper reference limit) with rise 
and or fall in cTnI concentration where serial testing 
was available AND symptoms OR signs of myocardial 
ischaemia  
 
 
Type 2 myocardial infarction 
 
Myocardial necrosis (any cTnI concentration above the 
upper reference limit) with rise and or fall in cTnI 
concentration where serial testing was available AND 
symptoms OR signs of myocardial ischaemia AND 
evidence of increased oxygen demand (e.g. 
tachyarrhythmia, hypertrophy) or reduced supply (e.g. 
hypotension, hypoxia or anaemia) in context of 
alternative clinical diagnosis 
 
 
Myocardial injury 
 
Myocardial necrosis (any cTnI concentration above the 
upper reference limit) without symptoms OR signs of 
myocardial ischaemia in context of alternative clinical 
diagnosis  
 
 
The process of adjudication was conducted by two cardiologists independently. Both had access to the 
electronic patient record. The adjudicated diagnosis was reached by evaluating the attending clinicians 
documentation of the presenting complaint, past medical history, cardiovascular risk factors and clinical 
examination findings including routine observations (pulse, blood pressure, pulse oximetry, temperature 
and conscious level). All investigation results undertaken by the attending clinician were available for 
review, including biochemistry and haematology results, the 12 lead electrocardiogram, echocardiogram, 
chest X-ray and invasive coronary angiography findings when performed. Both adjudicating cardiologists 
had access to the final discharge letter documenting the attending clinicians’ final diagnosis. We did not 
apply specific criteria to define supply or demand imbalance,1 but adjudicated myocardial supply or demand 
imbalance on an individual patient basis, in line with most studies in this area.2 
	Supplemental Appendix 3. Additional information on classification of cardiovascular 
death 
ICD Code Definition 
Ischaemic heart diseases 
I20 Angina pectoris 
I21 Acute myocardial infarction 
I22 Subsequent myocardial infarction 
I23 Certain current complications from acute myocardial infarction 
I24 Other acute ischaemic heart diseases 
I25 Chronic ischaemic heart disease 
Other forms of heart disease 
I34 Non-rheumatic mitral valve disorders 
I35 Non-rheumatic aortic valve disorders 
I36 Non-rheumatic tricuspid valve disorders 
I37 Pulmonary valve disorders 
I42 Cardiomyopathy 
I43 Cardiomyopathy in diseases classified elsewhere 
I46 Cardiac arrest 
I48 Atrial fibrillation and flutter 
I49 Other cardiac arrhythmias 
I50 Heart failure 
I51 Complications and ill-defined descriptions of heart disease 
Cerebrovascular diseases 
I60 Subarachnoid haemorrhage 
I61 Intracerebral haemorrhage 
I62 Other nontraumatic intracerebral haemorrhage 
I63 Cerebral infarction 
I64 Stroke, not specified as haemorrhage or infarction 
	I65 Occlusion and stenosis of precerebral arteries, not resulting in infarction 
I66 Occlusion and stenosis of cerebral arteries, not resulting in infarction 
I67 Other cerebrovascular diseases 
I68 Cerebrovascular disorders in diseases classified elsewhere 
I69 Sequelae of cerebrovascular disease 
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